Abstract

Objective To investigate the dose-response relationship of flurbiprofen for inhibiting postoperative hyperalgesia after remifentanil-based anesthesia in patients undergoing major abdominal surgery. Methods Fifty patients undergoing major abdominal surgery under remifentanil-based general anesthesia were studied. Anesthesia was induced with midazolam 0.05 mg/kg, propofol 2 mg/kg, fentanyl 4 μg/kg and cisatracurium 1 mg/kg and maintained with infusion of remifentail(0.25 μg·kg-1·min-1) and propofol(3-4 mg·kg-1·h-1). Cisatracurium was given intermittently. The patients were mechanically ventilated after tracheal intubation. Flurbiprofen was given before skin incision for inhibiting remifentanil-induced postoperative hyperalgesia. Pain was assessed using VAS at 10 min after tracheal extubation. VAS score <4 was defined as effective. The optimal dose was determined by Dixon’s up-and-down method. If the VAS score was<4, the next patient received a lower dose of flurbiprofen, or conversely if ineffective, a high dose was given in the next patient. The up-and-down sequences were analyzed by using probit method that determine the ED50, ED95 and 95% confidence interval(CI). Results The ED50 and ED95 of flurbiprofen for inhibiting postoperative hyperalgesia after remifentanil-based anesthesia in patients following gynecological laparoscopy were 1.40(95% CI=1.13- 1.61)mg/kg and 2.21(95% CI=1.89-3.33)mg/kg. Conclusion The ED50 and ED95 of flurbiprofen for inhibiting postoperative hyperalgesia after remifentanil-based anesthesia in patients following major abdominal surgery are 1.40 mg/kg and 2.21 mg/kg respectively. Key words: Flurbiprofen; Remifentanil; Hyperalgesia; Dose-response relationship

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.